Literature DB >> 25806330

Negative results of METLung study: an opportunity to better understand the role of MET pathway in advanced NSCLC.

Maurice Pérol1.   

Abstract

Entities:  

Year:  2014        PMID： 25806330      PMCID： PMC4367676          DOI： 10.3978/j.issn.2218-6751.2014.09.06

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  3 in total

Review 1.  Targeting MET in cancer: rationale and progress.

Authors:  Ermanno Gherardi; Walter Birchmeier; Carmen Birchmeier; George Vande Woude
Journal:  Nat Rev Cancer       Date:  2012-01-24       Impact factor: 60.716

2.  Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.

Authors:  David R Spigel; Thomas J Ervin; Rodryg A Ramlau; Davey B Daniel; Jerome H Goldschmidt; George R Blumenschein; Maciej J Krzakowski; Gilles Robinet; Benoit Godbert; Fabrice Barlesi; Ramaswamy Govindan; Taral Patel; Sergey V Orlov; Michael S Wertheim; Wei Yu; Jiping Zha; Robert L Yauch; Premal H Patel; See-Chun Phan; Amy C Peterson
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

3.  MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.

Authors:  F Cappuzzo; P A Jänne; M Skokan; G Finocchiaro; E Rossi; C Ligorio; P A Zucali; L Terracciano; L Toschi; M Roncalli; A Destro; M Incarbone; M Alloisio; A Santoro; M Varella-Garcia
Journal:  Ann Oncol       Date:  2008-10-03       Impact factor: 32.976
  3 in total
  9 in total

1.  Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial.

Authors:  Oscar Arrieta; Graciela Cruz-Rico; Enrique Soto-Perez-de-Celis; Laura-Alejandra Ramírez-Tirado; Enrique Caballe-Perez; Jorge-Negueb Martínez-Hernández; Ivan Martinez-Alvarez; Giovanny Soca-Chafre; Eleazar Omar Macedo-Pérez; Horacio Astudillo-de la Vega
Journal:  Target Oncol       Date:  2016-10       Impact factor: 4.493

2.  Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer.

Authors:  Julia Tchou; Yangbing Zhao; Bruce L Levine; Paul J Zhang; Megan M Davis; Jan Joseph Melenhorst; Irina Kulikovskaya; Andrea L Brennan; Xiaojun Liu; Simon F Lacey; Avery D Posey; Austin D Williams; Alycia So; Jose R Conejo-Garcia; Gabriela Plesa; Regina M Young; Shannon McGettigan; Jean Campbell; Robert H Pierce; Jennifer M Matro; Angela M DeMichele; Amy S Clark; Laurence J Cooper; Lynn M Schuchter; Robert H Vonderheide; Carl H June
Journal:  Cancer Immunol Res       Date:  2017-11-06       Impact factor: 11.151

3.  MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review.

Authors:  Jung Han Kim; Hyeong Su Kim; Bum Jun Kim
Journal:  Oncotarget       Date:  2017-09-11

4.  MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker.

Authors:  Stephan Macher-Goeppinger; Martina Keith; Volker Endris; Roland Penzel; Katrin E Tagscherer; Sascha Pahernik; Markus Hohenfellner; Humphrey Gardner; Carsten Grüllich; Peter Schirmacher; Wilfried Roth
Journal:  Oncotarget       Date:  2017-01-03

5.  Prognostic value of MET copy number gain in non-small-cell lung cancer: an updated meta-analysis.

Authors:  Jung Han Kim; Hyeong Su Kim; Bum Jun Kim
Journal:  J Cancer       Date:  2018-04-23       Impact factor: 4.207

Review 6.  MET Activation and Physical Dynamics of the Metastatic Process: The Paradigm of Cancers of Unknown Primary Origin.

Authors:  Giulia M Stella; Silvia Benvenuti; Alessandra Gentile; Paolo M Comoglio
Journal:  EBioMedicine       Date:  2017-09-21       Impact factor: 8.143

7.  Predicting ligand-dependent tumors from multi-dimensional signaling features.

Authors:  Helge Hass; Kristina Masson; Sibylle Wohlgemuth; Violette Paragas; John E Allen; Mark Sevecka; Emily Pace; Jens Timmer; Joerg Stelling; Gavin MacBeath; Birgit Schoeberl; Andreas Raue
Journal:  NPJ Syst Biol Appl       Date:  2017-09-20

8.  c-Met-targeted chimeric antigen receptor T cells inhibit hepatocellular carcinoma cells in vitro and in vivo.

Authors:  Xiaochen Huang; Jiaojiao Guo; Tao Li; Lizhou Jia; Xiaojun Tang; Jin Zhu; Qi Tang; Zhenqing Feng
Journal:  J Biomed Res       Date:  2021-12-16

9.  Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial.

Authors:  Manish A Shah; Yung-Jue Bang; Florian Lordick; Maria Alsina; Meng Chen; Stephen P Hack; Jean Marie Bruey; Dustin Smith; Ian McCaffery; David S Shames; See Phan; David Cunningham
Journal:  JAMA Oncol       Date:  2017-05-01       Impact factor: 31.777
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.